Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Amphastar Pharmaceuticals Inc. (AMPH) Insider Trading Activity

    Healthcare • Drug Manufacturers - Specialty & Generic • 1,761 employees

    Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

    Total Value

    -$6,830,984.50

    Total Shares

    281,977

    Average Trade Value

    -$145,340.10

    Most Active Insider

    Zhang Jack Y.

    Total Activity: $19,352,223

    Largest Single Transaction

    $6,032,758

    by Zhang Jack Y. on Mar 14, 2025

    30-Day Activity

    1 Transaction

    Volume: 500 shares
    Value: $14,190

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Apr 1, 2025 500 $14,190 73,909 (-0.7%) Sale
    Cfo, EVP Treasurer
    Mar 17, 2025 3,004 $83,181 125,258 (-2.4%) Payment of Exercise Price
    EVP Corp Admin Center
    Mar 17, 2025 1,731 $47,931 90,909 (-1.9%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 17, 2025 16,150 $447,194 2,647,659 (-0.6%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 17, 2025 7,223 $200,005 1,185,475 (-0.6%) Payment of Exercise Price
    Senior Evp, Production Center
    Mar 17, 2025 1,967 $54,466 137,497 (-1.4%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 15, 2025 9,765 $260,335 2,663,809 (-0.4%) Payment of Exercise Price
    Cfo, EVP Treasurer
    Mar 15, 2025 1,968 $52,467 128,262 (-1.5%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 15, 2025 4,115 $109,706 1,192,698 (-0.3%) Payment of Exercise Price
    Senior Evp, Production Center
    Mar 15, 2025 1,222 $32,579 139,464 (-0.9%) Payment of Exercise Price
    EVP Corp Admin Center
    Mar 15, 2025 1,031 $27,486 92,640 (-1.1%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 14, 2025 162,657 $4,336,436 1,196,813 (-13.6%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 14, 2025 226,285 $6,032,758 2,673,574 (-8.5%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 14, 2025 290,477 $4,267,107 2,899,859 (+10.0%) Exercise/Conversion
    CEO Chief Scientific Officer
    Mar 14, 2025 211,213 $3,102,719 1,359,470 (+15.5%) Exercise/Conversion
    EVP Corp Admin Center
    Mar 10, 2025 20,837 $10,000 93,671 (+22.2%) Grant
    CEO Chief Scientific Officer
    Mar 10, 2025 116,226 $10,000 2,609,382 (+4.5%) Grant
    Senior Evp, Production Center
    Mar 10, 2025 24,692 $10,000 140,686 (+17.6%) Grant
    CEO Chief Scientific Officer
    Mar 10, 2025 48,996 $0 1,148,257 (+4.3%) Grant
    Cfo, EVP Treasurer
    Mar 10, 2025 36,747 $10,000 130,230 (+28.2%) Grant
    Cfo, EVP Treasurer
    Mar 6, 2025 2,141 $60,633 93,483 (-2.3%) Payment of Exercise Price
    Mar 6, 2025 1,000 $27,986 74,409 (-1.3%) Sale
    CEO Chief Scientific Officer
    Mar 6, 2025 3,069 $86,914 1,099,261 (-0.3%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 6, 2025 9,645 $273,146 2,493,156 (-0.4%) Payment of Exercise Price
    EVP Corp Admin Center
    Mar 6, 2025 1,141 $32,313 72,834 (-1.6%) Payment of Exercise Price
    Senior Evp, Production Center
    Mar 6, 2025 1,354 $38,345 115,994 (-1.2%) Payment of Exercise Price
    Cfo, EVP Treasurer
    Mar 4, 2025 7,490 $99,992 101,594 (+7.4%) Exercise/Conversion
    Cfo, EVP Treasurer
    Mar 4, 2025 4,231 $116,515 97,363 (-4.3%) Sale
    Cfo, EVP Treasurer
    Mar 4, 2025 1,739 $48,031 95,624 (-1.8%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 4, 2025 2,426 $67,006 1,102,330 (-0.2%) Payment of Exercise Price
    Senior Evp, Production Center
    Mar 4, 2025 1,121 $30,962 117,348 (-1.0%) Payment of Exercise Price
    CEO Chief Scientific Officer
    Mar 4, 2025 5,753 $158,898 2,502,801 (-0.2%) Payment of Exercise Price
    EVP Corp Admin Center
    Mar 4, 2025 963 $26,598 73,975 (-1.3%) Payment of Exercise Price
    Senior Evp, Production Center
    Dec 13, 2024 8,000 $90,640 126,469 (+6.3%) Exercise/Conversion
    Senior Evp, Production Center
    Dec 13, 2024 8,000 $361,840 118,469 (-6.8%) Sale
    Senior Evp, Production Center
    Dec 12, 2024 7,000 $310,975 118,469 (-5.9%) Sale
    Senior Evp, Production Center
    Dec 12, 2024 7,000 $79,310 125,469 (+5.6%) Exercise/Conversion
    Dec 9, 2024 10,000 $437,702 30,471 (-32.8%) Sale
    Dec 9, 2024 10,000 $195,200 40,471 (+24.7%) Exercise/Conversion
    Nov 12, 2024 5,000 $243,986 31,471 (-15.9%) Sale
    Nov 12, 2024 2,500 $41,725 36,471 (+6.9%) Exercise/Conversion
    Senior Evp, Production Center
    Nov 12, 2024 6,893 $103,050 125,281 (+5.5%) Exercise/Conversion
    Senior Evp, Production Center
    Nov 12, 2024 6,893 $336,930 118,388 (-5.8%) Sale
    EVP Corp Admin Center
    Nov 6, 2024 5,214 $271,389 74,938 (-7.0%) Sale
    EVP Corp Admin Center
    Nov 6, 2024 5,214 $67,938 80,152 (+6.5%) Exercise/Conversion
    Cfo, EVP Treasurer
    Nov 6, 2024 7,426 $386,523 94,103 (-7.9%) Sale
    Cfo, EVP Treasurer
    Nov 6, 2024 7,426 $96,761 101,529 (+7.3%) Exercise/Conversion